Written questions by Andrew.

Pursuant to the Answer of 2 December 2025 to Question 93697, if he will meet with representatives of ArchAngel MLD Trust, the MPS Society, MLD Support UK, the LSD Collaborative, and Alex – The Leukodystrophy Charity before responding to the UK National Screening Committee’s forthcoming recommendation on Metachromatic Leukodystrophy.

My rt. Hon. Friend, the Secretary of State for Health and Social Care, will carefully consider a UK National Screening Committee (UK NSC) recommendation on metachromatic leukodystrophy when it is presented to him, before making a decision. The Secretary of State will ask officials to meet with representatives of ArchAngel MLD Trust, the MPS Society, MLD Support UK, the LSD Collaborative, and Alex – The Leukodystrophy Charity.

Who his Department plans to consult as part of any review into the prevalence and overdiagnosis of mental health conditions and neurodivergence.

The independent review into prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism will appoint an advisory working group. This will be a multidisciplinary group of leading academics, clinicians, epidemiological experts, charities and people with lived experience to directly shape the recommendations and scrutinise the evidence.Ahead of launching the independent review, my Rt Hon. Friend, the Secretary of State for Health and Social Care, held discussions with a range of mental health, ADHD, and autism stakeholders on the scope of the review.As this is an independent review, it is therefore for the Chair and vice-chairs to consider who to consult and the relevant forums for engagement, that are relevant to deliver the terms of reference set by the Department.

What assessment he has made of the potential impact of not extending Start for Life funding to all councils delivering Best Start Family Hubs on (i) the developmental domains assessed in the Early Years Foundation Stage profile and (ii) the government’s commitment to shift from treatment to prevention.

We are committed to delivering the 10-Year Health Plan ambition to match Healthy Babies, formerly Start for Life, to Best Start Family Hubs over the next decade.There is strong evidence that the 1,001 days from pregnancy to the age of two years old set the foundations for our cognitive, emotional, and physical development. Supporting babies and their families in this period provides an opportunity to improve health and education outcomes and reduce inequalities, including on Early Years Foundation Stage domains.We have already started to deliver the shift from treatment to prevention by providing funding to 75 areas to deliver universal, prevention-focussed Healthy Babies services. From April, the Government is rolling out Best Start Family Hubs to all local authorities, backed by over £500 million to reach up to half a million more children and families. This funding will help embed hubs within a wider support system, including integrated child health services, and will enable proactive identification and support for health issues and early developmental delays.

To ask the Secretary of State for Health and Social Care what recent discussions he has had with the mental health sector on diagnoses of mental health conditions.

The independent review into prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism will appoint an advisory working group. This will be a multidisciplinary group of leading academics, clinicians, epidemiological experts, charities and people with lived experience to directly shape the recommendations and scrutinise the evidence.Ahead of launching the independent review, my Rt Hon. Friend, the Secretary of State for Health and Social Care, held discussions with a range of mental health, ADHD, and autism stakeholders on the scope of the review.As this is an independent review, it is therefore for the Chair and vice-chairs to consider who to consult and the relevant forums for engagement, that are relevant to deliver the terms of reference set by the Department.

Whether it is his intention to expand Start for Life funding to the 78 local authorities currently without provision.

The 10-Year Health Plan sets out an ambitious agenda on how we will improve the nation’s health by creating a new model of care that is fit for the future.We recognise that local authorities are ambitious, seeking to deliver universal support to families and prevent escalating need. We are committed to delivering the 10-Year Health Plan’s ambition to match Healthy Babies, formerly Start for Life, to Best Start Family Hubs over the next decade.From April, this Government is rolling out Best Start Family Hubs to all local authorities, backed by over £500 million to reach up to half a million more children and families. This funding will help embed Hubs within a wider support system, including integrated child health services, enable proactive identification and support for health issues and early developmental delays.

What assessment his Department has made of ambulance response times in rural areas of the East Midlands; and what steps are being taken to improve response times in those communities.

We acknowledge that ambulance performance has not consistently met expectations in recent years, and we are taking serious steps to improve performance across the country, including rural and semi-urban areas. That is why we published our Urgent and Emergency Care Plan for 2025/26, backed by almost £450 million of capital investment, which commits to reducing ambulance response times for Category 2 incidents to 30 minutes on average this year.The NHS Constitutional standards for ambulance response time metrics are measured with an average figure as well as a 90th centile standard which means that trusts are held to account for the response times they provide to all patients, improving the performance management of the ‘long tail’ of delayed ambulance responses that we know can particularly affect rural and semi-urban areas. In the East Midlands, the latest NHS England figures show a 22-minute improvement in the Category 2 90th centile response time compared with last year.We have already seen improvements in ambulance response times for the East Midlands Ambulance Service NHS Foundation Trust (EMAS). The latest National Health Service performance figures for EMAS show that Category 2 incidents were responded to in 46 minutes and 55 seconds on average, over 11 minutes faster than the same period last year.

What the average ambulance response time for Category 2 calls was in rural parts of the East Midlands in each of the last 12 months; and how this compares with response times in urban areas in the region.

We acknowledge that ambulance performance has not consistently met expectations in recent years, and we are taking serious steps to improve performance across the country, including rural and semi-urban areas. That is why we published our Urgent and Emergency Care Plan for 2025/26, backed by almost £450 million of capital investment, which commits to reducing ambulance response times for Category 2 incidents to 30 minutes on average this year.The NHS Constitutional standards for ambulance response time metrics are measured with an average figure as well as a 90th centile standard which means that trusts are held to account for the response times they provide to all patients, improving the performance management of the ‘long tail’ of delayed ambulance responses that we know can particularly affect rural and semi-urban areas. In the East Midlands, the latest NHS England figures show a 22-minute improvement in the Category 2 90th centile response time compared with last year.We have already seen improvements in ambulance response times for the East Midlands Ambulance Service NHS Foundation Trust (EMAS). The latest National Health Service performance figures for EMAS show that Category 2 incidents were responded to in 46 minutes and 55 seconds on average, over 11 minutes faster than the same period last year.

What steps his Department is taking to address regional and rural-urban disparities in ambulance response times, with reference to the performance of East Midlands Ambulance Service.

We acknowledge that ambulance performance has not consistently met expectations in recent years, and we are taking serious steps to improve performance across the country, including rural and semi-urban areas. That is why we published our Urgent and Emergency Care Plan for 2025/26, backed by almost £450 million of capital investment, which commits to reducing ambulance response times for Category 2 incidents to 30 minutes on average this year.The NHS Constitutional standards for ambulance response time metrics are measured with an average figure as well as a 90th centile standard which means that trusts are held to account for the response times they provide to all patients, improving the performance management of the ‘long tail’ of delayed ambulance responses that we know can particularly affect rural and semi-urban areas. In the East Midlands, the latest NHS England figures show a 22-minute improvement in the Category 2 90th centile response time compared with last year.We have already seen improvements in ambulance response times for the East Midlands Ambulance Service NHS Foundation Trust (EMAS). The latest National Health Service performance figures for EMAS show that Category 2 incidents were responded to in 46 minutes and 55 seconds on average, over 11 minutes faster than the same period last year.

Whether organisations in the mental health sector will be asked to contribute evidence to the Department’s review into the over-diagnosis of mental health conditions and neurodivergence.

My Rt Hon. Friend, the Secretary of State for Health and Social Care announced on 4 December 2025, via a Written Ministerial Statement, the launch of an independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism.The Government is deeply concerned that many adults, young people, and children with mental health conditions, ADHD, and autism have been let down by services and are not receiving timely or appropriate support and treatment. Therefore, we are launching this review to understand the rise in the prevalence and demand for services, so people receive the right support at the right time and in the right place.The review will look to understand, with regard to mental health conditions, ADHD and autism, the similarities and differences regarding prevalence, early intervention and treatment, the current challenges facing clinical services, and the extent to which diagnosis, medicalisation, and treatment improve outcomes for individuals.Professor Peter Fonagy will chair the review with the support of two vice chairs, Professor Sir Simon Wessely and Professor Gillian Baird. The review will appoint an advisory working group of leading academics, clinicians, epidemiological experts, charities, and people with lived experience to directly shape the recommendations and scrutinise the evidence. The Terms of Reference have been published on GOV.UK website and are available at the following link:https://www.gov.uk/government/publications/independent-review-into-mental-health-conditions-adhd-and-autism-terms-of-reference

If he will publish the proposed scope and timetable for his Department’s review into the prevalence of the potential over-diagnosis of mental health conditions and neurodivergence.

My Rt Hon. Friend, the Secretary of State for Health and Social Care announced on 4 December 2025, via a Written Ministerial Statement, the launch of an independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism.The Government is deeply concerned that many adults, young people, and children with mental health conditions, ADHD, and autism have been let down by services and are not receiving timely or appropriate support and treatment. Therefore, we are launching this review to understand the rise in the prevalence and demand for services, so people receive the right support at the right time and in the right place.The review will look to understand, with regard to mental health conditions, ADHD and autism, the similarities and differences regarding prevalence, early intervention and treatment, the current challenges facing clinical services, and the extent to which diagnosis, medicalisation, and treatment improve outcomes for individuals.Professor Peter Fonagy will chair the review with the support of two vice chairs, Professor Sir Simon Wessely and Professor Gillian Baird. The review will appoint an advisory working group of leading academics, clinicians, epidemiological experts, charities, and people with lived experience to directly shape the recommendations and scrutinise the evidence. The Terms of Reference have been published on GOV.UK website and are available at the following link:https://www.gov.uk/government/publications/independent-review-into-mental-health-conditions-adhd-and-autism-terms-of-reference

What plans his Department has to consult stakeholders in the mental health and neurodivergence sectors as part of its review into over-diagnosis.

My Rt Hon. Friend, the Secretary of State for Health and Social Care announced on 4 December 2025, via a Written Ministerial Statement, the launch of an independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism.The Government is deeply concerned that many adults, young people, and children with mental health conditions, ADHD, and autism have been let down by services and are not receiving timely or appropriate support and treatment. Therefore, we are launching this review to understand the rise in the prevalence and demand for services, so people receive the right support at the right time and in the right place.The review will look to understand, with regard to mental health conditions, ADHD and autism, the similarities and differences regarding prevalence, early intervention and treatment, the current challenges facing clinical services, and the extent to which diagnosis, medicalisation, and treatment improve outcomes for individuals.Professor Peter Fonagy will chair the review with the support of two vice chairs, Professor Sir Simon Wessely and Professor Gillian Baird. The review will appoint an advisory working group of leading academics, clinicians, epidemiological experts, charities, and people with lived experience to directly shape the recommendations and scrutinise the evidence. The Terms of Reference have been published on GOV.UK website and are available at the following link:https://www.gov.uk/government/publications/independent-review-into-mental-health-conditions-adhd-and-autism-terms-of-reference

What recent discussions he has had with representatives of the mental health and neurodivergence sectors on over-diagnosis.

My Rt Hon. Friend, the Secretary of State for Health and Social Care announced on 4 December 2025, via a Written Ministerial Statement, the launch of an independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism.The Government is deeply concerned that many adults, young people, and children with mental health conditions, ADHD, and autism have been let down by services and are not receiving timely or appropriate support and treatment. Therefore, we are launching this review to understand the rise in the prevalence and demand for services, so people receive the right support at the right time and in the right place.The review will look to understand, with regard to mental health conditions, ADHD and autism, the similarities and differences regarding prevalence, early intervention and treatment, the current challenges facing clinical services, and the extent to which diagnosis, medicalisation, and treatment improve outcomes for individuals.Professor Peter Fonagy will chair the review with the support of two vice chairs, Professor Sir Simon Wessely and Professor Gillian Baird. The review will appoint an advisory working group of leading academics, clinicians, epidemiological experts, charities, and people with lived experience to directly shape the recommendations and scrutinise the evidence. The Terms of Reference have been published on GOV.UK website and are available at the following link:https://www.gov.uk/government/publications/independent-review-into-mental-health-conditions-adhd-and-autism-terms-of-reference

If he will publish the terms of reference for the Department’s review into the prevalence and potential over-diagnosis of mental health conditions and neurodivergence.

My Rt Hon. Friend, the Secretary of State for Health and Social Care announced on 4 December 2025, via a Written Ministerial Statement, the launch of an independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism.The Government is deeply concerned that many adults, young people, and children with mental health conditions, ADHD, and autism have been let down by services and are not receiving timely or appropriate support and treatment. Therefore, we are launching this review to understand the rise in the prevalence and demand for services, so people receive the right support at the right time and in the right place.The review will look to understand, with regard to mental health conditions, ADHD and autism, the similarities and differences regarding prevalence, early intervention and treatment, the current challenges facing clinical services, and the extent to which diagnosis, medicalisation, and treatment improve outcomes for individuals.Professor Peter Fonagy will chair the review with the support of two vice chairs, Professor Sir Simon Wessely and Professor Gillian Baird. The review will appoint an advisory working group of leading academics, clinicians, epidemiological experts, charities, and people with lived experience to directly shape the recommendations and scrutinise the evidence. The Terms of Reference have been published on GOV.UK website and are available at the following link:https://www.gov.uk/government/publications/independent-review-into-mental-health-conditions-adhd-and-autism-terms-of-reference

Whether his Department is undertaking a review into the prevalence of the over-diagnosis of mental health conditions and neurodivergence.

My Rt Hon. Friend, the Secretary of State for Health and Social Care announced on 4 December 2025, via a Written Ministerial Statement, the launch of an independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism.The Government is deeply concerned that many adults, young people, and children with mental health conditions, ADHD, and autism have been let down by services and are not receiving timely or appropriate support and treatment. Therefore, we are launching this review to understand the rise in the prevalence and demand for services, so people receive the right support at the right time and in the right place.The review will look to understand, with regard to mental health conditions, ADHD and autism, the similarities and differences regarding prevalence, early intervention and treatment, the current challenges facing clinical services, and the extent to which diagnosis, medicalisation, and treatment improve outcomes for individuals.Professor Peter Fonagy will chair the review with the support of two vice chairs, Professor Sir Simon Wessely and Professor Gillian Baird. The review will appoint an advisory working group of leading academics, clinicians, epidemiological experts, charities, and people with lived experience to directly shape the recommendations and scrutinise the evidence. The Terms of Reference have been published on GOV.UK website and are available at the following link:https://www.gov.uk/government/publications/independent-review-into-mental-health-conditions-adhd-and-autism-terms-of-reference

What evidence his Department has received on the potential over-diagnosis of mental health conditions and neurodivergence.

The most recent evidence about the prevalence of mental health conditions and neurodiversity comes from the Adult Psychiatric Morbidity Survey 2023/24, which provides data on the prevalence of both treated and untreated mental health disorders and neurodevelopmental conditions in the English adult population.The survey found that common mental health conditions among adults, especially young adults, have become more widespread over time. There has also been a noticeable increase in the number of adults screening positive for attention deficit hyperactivity disorder (ADHD). In contrast, the prevalence of autism in adults has remained steady over the years.We are deeply concerned that many adults, young people, and children with mental health conditions, ADHD, and autism have been let down by services and are not receiving timely or appropriate support and treatment. That is why we have launched an independent review into the prevalence and support for mental health conditions, ADHD, and autism.The review will examine the similarities and differences between mental health conditions, ADHD, and autism, focusing on prevalence, prevention, treatment, and current challenges in clinical services. It will assess how diagnosis, medicalisation, and treatment impact individual outcomes, including the risks and benefits of medicalisation, and will identify approaches to provide varied support models and pathways, both within and beyond the National Health Service, that promote prevention and early intervention alongside clinical care.

What recent assessment he has made of the potential implications for his policies of changes in the diagnosis rates of mental health conditions and neurodivergence in England in the last five years.

No assessment has been made. The independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder, and autism will examine the similarities and differences between these conditions, focusing on prevalence, prevention, treatment, and current challenges in clinical services.It will assess how diagnosis, medicalisation, and treatment impact individual outcomes, including the risks and benefits of medicalisation, and will identify approaches to provide varied support models and pathways, both within and beyond the National Health Service, that promote prevention and early intervention alongside clinical care.The report will include recommendations for responding to rising need, both within the Government and across the health system and wider public services.

What meetings or engagements Ministers or senior officials from his department have had with any of the following patient organisations to discuss newborn screening: (a) Genetic Alliance UK (b) UK LSD Collaborative (c) UK Newborn Screening Collaborative (d) ArchAngel MLD Trust (e) MPS Society (f) MLD Support Association UK (g) SMA UK (h) Immunodeficiency UK (i) Alex, The Leukodystrophy Charity (j) Metabolic Support UK, since July 2024.

The Government remains committed to improving the lives of people living with rare diseases through the UK Rare Diseases Framework, which includes faster diagnosis as one of its four priorities.In all aspects of population and targeted screening, ministers are advised by the UK National Screening Committee (UK NSC). When assessing the case for newborn screening for rare diseases, as with all other diseases and conditions, the UK NSC uses internationally recognised criteria and a rigorous evidence review and consultation process. It is only where the UK NSC is confident that the offer to screen provides more good than harm that a screening programme is recommended. When the UK NSC makes a screening recommendation, ministers are then asked to consider and make a decision on whether to accept the recommendation.This year, the UK NSC secretariat carried out a review of the committee’s stakeholder engagement strategy and activities. The review included an online survey and three focused stakeholder discussion groups that were attended by a total of 17 external stakeholders, including seven representatives of patient organisations representing rare diseases affecting newborns. The UK NSC stakeholder strategy is being updated to incorporate their valuable feedback and is expected to be published in early 2026.Although the Department screening team supporting the UK NSC has limited capacity to meet with individual stakeholders, they actively involve and engage with stakeholders and partners in other ways. For example:a representative of Genetic Alliance UK sits on the UK NSC Blood Spot Task Group;the CEO of SMA UK is on the SMA Partnership Board;a representative from Immunodeficiency UK is on the Severe Combined Immunodeficiency In Service Evaluation board; andthe following organisations all contributed to the metachromatic leukodystrophy (MLD) screening consultation earlier this year: ArchAngel MLD Trust; MPS Society; MLD Support UK; LSD Collaborative; Alex, The Leukodystrophy Charity; and the UK Newborn Screening Laboratory Network.The Department screening team meets regularly with the Department’s rare diseases team to discuss overlapping areas of work. The rare diseases team have working relationships with the wider rare diseases community and junior officials have met with Genetic Alliance UK.

What steps his Department has taken to ensure the National Screening Committee and the newborn screening programme appropriately consider rare diseases.

When assessing the case for newborn screening for rare diseases, as with all other diseases and conditions, the UK National Screening Committee (UK NSC) uses internationally recognised criteria, and a rigorous evidence review and consultation process. It is only where the UK NSC is confident that the offer to screen provides more good than harm that a screening programme is recommended.The UK NSC is an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening and supports implementation.

What assessment he has made of the potential impact of (a) the Government’s plans to bring NHS England into the Department of Health and Social Care and (b) the planned 50% reduction in integrated care board staffing on those boards’ capacity to safeguard children, including their effective participation in multi-agency child protection teams proposed in the Children’s Wellbeing and Schools Bill.

The Government will publish an impact assessment of its plan to bring NHS England into the Department alongside the primary legislation to enact this reform. We do not expect the integration to have an impact on the capacity of integrated care boards (ICBs) to safeguard children, as the existing safeguarding functions of ICBs will be retained.To ensure ICBs maintain effective safeguarding functions throughout the reform, NHS England has shared best practice on safeguarding with ICBs earlier this year. In November 2025, NHS England also published a strategic commissioning framework for ICBs with a focus on collaboration with local government and wider system partners.Safeguarding partners, including health, have a legal duty to work together to safeguard and promote children’s welfare, including through the proposed Multi Agency Child Protection Teams. There is no intention to change this duty through the ICB reform.

For what reason Candidozyma auris was added to schedule 2 of the Health Protection (Notification) Regulations in April 2025;and if he will publish any public health risk assessments informing that decision.

Candidozyma, formerly Candida, auris is an emerging multi-drug resistant fungal pathogen. Candidozyma auris is becoming more widespread globally, can result in serious infections in vulnerable individuals, and has been associated with outbreaks in healthcare settings that have resulted in substantial service disruption. The addition of candidozyma auris to the Health Protection (Notification) Regulations as a notifiable organism under Schedule 2 enables the UK Health Security Agency to more closely monitor this pathogen and inform public health action to limit its spread within the United Kingdom. The Health Protection (Notification) (Amendment) Regulations 2025 Impact Assessment, a copy of which is attached, highlights that testing for candidozyma auris would be conducted within National Health Service and private laboratories. The burden on laboratories for additional testing is likely to be low, as testing is straightforward.